|   LifeSciVC

Sharing An Innate Desire To Address Inflammation: Novartis and IFM Team Up

By Bruce Booth, DPhil, Partner


Today Novartis announced the acquisition of IFM Therapeutics’ portfolio of NLRP3 antagonists, via the purchase of IFM Tre, a subsidiary of IFM (here, here). These immunomodulatory medicines target the inflammasome, a key innate immune node whose pathologic chronic activation is associated with several metabolic, fibrotic, autoimmune, and neurological diseases.

Read more.